Obstet Gynecol Sci.  2023 Nov;66(6):463-476. 10.5468/ogs.23117.

Cytomegalovirus infection during pregnancy

• Choodinatha HK
• Jeon MR
• Choi BY
• Lee KN
• Kim HJ
• Park JY

• KMID: 2547848
• DOI: http://doi.org/10.5468/ogs.23117

Abstract

Cytomegalovirus (CMV) infection during pregnancy is a global silent problem. Additionally, it is the leading cause of congenital infections, non-genetic sensorineural hearing loss, and neurodevelopmental delays in infants. However, this has barely been recognized globally. This condition lacks adequate attention, which is further emphasized by the lack of awareness among healthcare workers and the general population. The impact of CMV infection is often overlooked because of the asymptomatic nature of its presentation in infected pregnant women and newborns, difficulty in diagnosis, and the perception that infants born to women with pre-existing antibodies against CMV have normal neonatal outcomes. This article highlights the latest information on the epidemiology, transmission, clinical manifestations, and development of CMV infection and its management. We reviewed the pathophysiology and clinical manifestations of CMV infection in pregnant women, diagnostic methods, including screening and prognostic markers, and updates in treatment modalities. Current advancements in research on vaccination and hyperimmunoglobulins with worldwide treatment protocols are highlighted.

Keyword

Cytomegalovirus; Pregnancy; Microcephaly; Hearing loss; Acyclovir; Valacyclovir

Figure

• 

  Fig. 1 Transmission mechanisms and treatment protocols for CMV infection during pregnancy. CMV, cytomegalovirus; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumor necrosis factor alpha; IUGR, intrauterine growth restriction; IgG, immunoglobulin G; IgM, immunoglobulin M; RT-PCR, reverse transcription polymerase chain reaction; MRI, magnetic resonance imaging; CNS, central nervous system.

• 

  Fig. 2 Flow chart for the interpretation of the maternal cytomegalovirus (CMV) serology test results. IgG, immunoglobulin G; IgM, immunoglobulin M.

Reference

References

1. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007; 17:355–63.

2. Stagno S. Cytomegalovirus infection: a pediatrician’s perspective. Curr Probl Pediatr. 1986; 16:629–67.

3. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007; 17:253–76.

4. Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020; 223:330–49.

5. Korver AM, de Vries JJ, Konings S, de Jong JW, Dekker FW, Vossen AC, et al. DECIBEL study: congenital cytomegalovirus infection in young children with permanent bilateral hearing impairment in the Netherlands. J Clin Virol. 2009; 46(Suppl 4):S27–31.

6. Goderis J, De Leenheer E, Smets K, Van Hoecke H, Keymeulen A, Dhooge I. Hearing loss and congenital CMV infection: a systematic review. Pediatrics. 2014; 134:972–82.

7. Avettand-Fenoël V, Marlin S, Vauloup-Fellous C, Loundon N, François M, Couloigner V, et al. Congenital cytomegalovirus is the second most frequent cause of bilateral hearing loss in young French children. J Pediatr. 2013; 162:593–9.

8. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de Carvalho e Oliveira PF, Boppana S, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis. 2009; 49:522–8.

9. Cherry J, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ. Feigin and cherry’s textbook of pediatric infectious diseases e-book: 2-volume set. 7th ed. Amsterdam: Elsevier Health Sciences;2013.

10. Waters A, Jennings K, Fitzpatrick E, Coughlan S, Molloy EJ, De Gascun CF, et al. Incidence of congenital cytomegalovirus infection in Ireland: implications for screening and diagnosis. J Clin Virol. 2014; 59:156–60.

11. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010; 20:202–13.

12. Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis. 1995; 20:665–70.

13. Damato EG, Winnen CW. Cytomegalovirus infection: perinatal implications. J Obstet Gynecol Neonatal Nurs. 2002; 31:86–92.

14. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis. 2011; 52:e11–3.

15. Picone O, Vauloup-Fellous C, Cordier AG, Guitton S, Senat MV, Fuchs F, et al. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn. 2013; 33:751–8.

16. Yinon Y, Farine D, Yudin MH. No. 240-cytomegalovirus infection in pregnancy. J Obstet Gynaecol Can. 2018; 40:e134–41.

17. Gaytant MA, Steegers EA, Semmekrot BA, Merkus HM, Galama JM. Congenital cytomegalovirus infection: review of the epidemiology and outcome. Obstet Gynecol Surv. 2002; 57:245–56.

18. Kagan KO, Hamprecht K. Cytomegalovirus infection in pregnancy. Arch Gynecol Obstet. 2017; 296:15–26.

19. Rawlinson WD, Hamilton ST, van Zuylen WJ. Update on treatment of cytomegalovirus infection in pregnancy and of the newborn with congenital cytomegalovirus. Curr Opin Infect Dis. 2016; 29:615–24.

20. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA. 2003; 289:1008–11.

21. Pass RF. Cytomegalovirus infection. Pediatr Rev. 2002; 23:163–70.

22. Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Virol. 2000; 74:6808–20.

23. Maschmann J, Hamprecht K, Dietz K, Jahn G, Speer CP. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin Infect Dis. 2001; 33:1998–2003.

24. Jim WT, Chiu NC, Ho CS, Shu CH, Chang JH, Hung HY, et al. Outcome of preterm infants with postnatal cytomegalovirus infection via breast milk: a two-year prospective follow-up study. Medicine (Baltimore). 2015; 94:e1835.

25. Kurath S, Halwachs-Baumann G, Müller W, Resch B. Transmission of cytomegalovirus via breast milk to the prematurely born infant: a systematic review. Clin Microbiol Infect. 2010; 16:1172–8.

26. Enders G, Daiminger A, Bäder U, Exler S, Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol. 2011; 52:244–6.

27. Khalil A, Sotiriadis A, Chaoui R, da Silva Costa F, D’Antonio F, Heath PT, et al. ISUOG practice guidelines: role of ultrasound in congenital infection. Ultrasound Obstet Gynecol. 2020; 56:128–51.

28. Hamilton ST, Scott G, Naing Z, Iwasenko J, Hall B, Graf N, et al. Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. PLos One. 2012; 7:e52899.

29. Emery VC, Lazzarotto T. Cytomegalovirus in pregnancy and the neonate. F1000Res. 2017; 6:138.

30. Feldman B, Yinon Y, Tepperberg Oikawa M, Yoeli R, Schiff E, Lipitz S. Pregestational, periconceptional, and gestational primary maternal cytomegalovirus infection: prenatal diagnosis in 508 pregnancies. Am J Obstet Gynecol. 2011; 205:342.e1–6.

31. Navti OB, Al-Belushi M, Konje JC. Cytomegalovirus infection in pregnancy - an update. Eur J Obstet Gynecol Reprod Biol. 2021; 258:216–22.

32. Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol. 2016; 214:B5–11.

33. Adler SP, Lewis N, Conlon A, Christiansen MP, Al-Ibrahim M, Rupp R, et al. V160-001 study group. Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects. J Infect Dis. 2019; 220:411–9.

34. Chiopris G, Veronese P, Cusenza F, Procaccianti M, Perrone S, Daccò V, et al. Congenital cytomegalovirus infection: update on diagnosis and treatment. Microorganisms. 2020; 8:1516.

35. Zelini P, d’Angelo P, De Cicco M, Achille C, Sarasini A, Fiorina L, et al. Human cytomegalovirus non-primary infection during pregnancy: antibody response, risk factors and newborn outcome. Clin Microbiol Infect. 2022; 28:1375–81.

36. Picone O, Grangeot-Keros L, Senat M, Fuchs F, Bouthry E, Ayoubi J, et al. Cytomegalovirus non-primary infection during pregnancy. Can serology help with diagnosis? J Matern Fetal Neonatal Med. 2017; 30:224–7.

37. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009; 22:99–126.

38. Blázquez-Gamero D, Soriano-Ramos M, Martínez de Aragón A, Baquero-Artigao F, Frick MA, Noguera-Julian A, et al. Role of magnetic resonance imaging and cranial ultrasonography in congenital cytomegalovirus infection. Pediatr Infect Dis J. 2019; 38:1131–7.

39. Cho GJ, Oh MJ, Chung JW, Chung OS, Lee JK, Hur JY, et al. A case of congenital cytomegalovirus infection with severe hydrocephalus in prenatal ultrasonography. Korean J Obstet Gynecol. 2004; 2224–8.

40. Hawkins-Villarreal A, Moreno-Espinosa AL, Martinez-Portilla RJ, Castillo K, Hahner N, Nakaki A, et al. Fetal liver volume assessment using magnetic resonance imaging in fetuses with cytomegalovirus infection^†. Front Med (Lausanne). 2022; 9:889976.

41. Gabrielli L, Bonasoni MP, Chiereghin A, Piccirilli G, Borgatti EC, Simonazzi G, et al. Pathophysiology of hyperechogenic bowel in congenitally human cytomegalovirus infected fetuses. Microorganisms. 2020; 8:779.

42. Prodan N, Sonek J, Wagner P, Hoopmann M, Abele H, Hamprecht K, et al. Splenic artery blood flow as a potential marker for materno-fetal transmission of a primary CMV infection. Arch Gynecol Obstet. 2019; 299:1289–94.

43. Boucoiran I, Yudin M, Poliquin V, Caddy S, Gantt S, Castillo E. Guideline no. 420: cytomegalovirus infection in pregnancy. J Obstet Gynaecol Can. 2021; 43:893–908.

44. Marsico C, Kimberlin DW. Congenital cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment. Ital J Pediatr. 2017; 43:38.

45. Foulon I, Vleurinck L, Kerkhofs K, Gordts F. Hearing configuration in children with cCMV infection and proposal of a flow chart for hearing evaluation. Int J Audiol. 2015; 54:714–9.

46. Cohen BE, Durstenfeld A, Roehm PC. Viral causes of hearing loss: a review for hearing health professionals. Trends Hear. 2014; 18:2331216514541361.

47. Foulon I, Naessens A, Faron G, Foulon W, Jansen AC, Gordts F. Hearing thresholds in children with a congenital CMV infection: a prospective study. Int J Pediatr Otorhinolaryngol. 2012; 76:712–7.

48. Goderis J, Keymeulen A, Smets K, Van Hoecke H, De Leenheer E, Boudewyns A, et al. Hearing in children with congenital cytomegalovirus infection: results of a longitudinal study. J Pediatr. 2016; 172:110–5.e2.

49. Foulon I, De Brucker Y, Buyl R, Lichtert E, Verbruggen K, Piérard D, et al. Hearing loss with congenital cytomegalovirus infection. Pediatrics. 2019; 144:e20183095.

50. Benoist G, Salomon LJ, Mohlo M, Suarez B, Jacquemard F, Ville Y. Cytomegalovirus-related fetal brain lesions: comparison between targeted ultrasound examination and magnetic resonance imaging. Ultrasound Obstet Gynecol. 2008; 32:900–5.

51. Picone O, Simon I, Benachi A, Brunelle F, Sonigo P. Comparison between ultrasound and magnetic resonance imaging in assessment of fetal cytomegalovirus infection. Prenat Diagn. 2008; 28:753–8.

52. Leruez-Ville M, Stirnemann J, Sellier Y, Guilleminot T, Dejean A, Magny JF, et al. Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis. Am J Obstet Gynecol. 2016; 215:342.e1–9.

53. Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth. 2013; 13:96.

54. Picone O, Vauloup-Fellous C, Cordier AG, Parent Du Châtelet I, Senat MV, Frydman R, et al. A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. BJOG. 2009; 116:818–23.

55. Vauloup-Fellous C, Picone O, Cordier AG, Parent-du-Châtelet I, Senat MV, Frydman R, et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. J Clin Virol. 2009; 46(Suppl 4):S49–53.

56. Reichman O, Miskin I, Sharoni L, Eldar-Geva T, Goldberg D, Tsafrir A, et al. Preconception screening for cytomegalovirus: an effective preventive approach. BioMed Res Int. 2014; 2014:135416.

57. Leruez-Ville M, Sellier Y, Salomon LJ, Stirnemann JJ, Jacquemard F, Ville Y. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort. Clin Infect Dis. 2013; 56:1428–35.

58. Grangeot-Keros L, Mayaux MJ, Lebon P, Freymuth F, Eugene G, Stricker R, et al. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J Infect Dis. 1997; 175:944–6.

59. Ely JW, Yankowitz J, Bowdler NC. Evaluation of pregnant women exposed to respiratory viruses. Am Fam Physician. 2000; 61:3065–74.

60. Guerra B, Simonazzi G, Puccetti C, Lanari M, Farina A, Lazzarotto T, et al. Ultrasound prediction of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol. 2008; 198:380.e1–7.

61. Picone O, Teissier N, Cordier AG, Vauloup-Fellous C, Adle-Biassette H, Martinovic J, et al. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. Prenat Diagn. 2014; 34:518–24.

62. Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect. 2011; 17:1285–93.

63. Enders G, Bäder U, Lindemann L, Schalasta G, Daiminger A. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. Prenat Diagn. 2001; 21:362–77.

64. Liesnard C, Donner C, Brancart F, Gosselin F, Delforge ML, Rodesch F. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol. 2000; 95(6 Pt 1):881–8.

65. Luck SE, Wieringa JW, Blázquez-Gamero D, Henneke P, Schuster K, Butler K, et al. Congenital cytomegalovirus: a European expert consensus statement on diagnosis and management. Pediatr Infect Dis J. 2017; 36:1205–13.

66. Leruez-Ville M, Magny JF, Couderc S, Pichon C, Parodi M, Bussières L, et al. Risk factors for congenital cytomegalovirus infection following primary and nonprimary maternal infection: a prospective neonatal screening study using polymerase chain reaction in saliva. Clin Infect Dis. 2017; 65:398–404.

67. Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017; 17:e177–88.

68. Hertel L. Human cytomegalovirus tropism for mucosal myeloid dendritic cells. Rev Med Virol. 2014; 24:379–95.

69. Blanco-Lobo P, Bulnes-Ramos Á, McConnell MJ, Navarro D, Pérez-Romero P. Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design. Drug Discov Today. 2016; 21:674–81.

70. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2010; 84:1005–13.

71. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, Campanini G, et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol. 2008; 89(Pt 4):853–65.

72. Fu TM, An Z, Wang D. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine. 2014; 32:2525–33.

73. Plotkin SA, Boppana SB. Vaccination against the human cytomegalovirus. Vaccine. 2019; 37:7437–42.

74. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol. 2004; 78:10023–33.

75. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A. 2005; 102:18153–8.

76. Barber V, Calvert A, Vandrevala T, Star C, Khalil A, Griffiths P, et al. Prevention of acquisition of cytomegalovirus infection in pregnancy through hygiene-based behavioral interventions: a systematic review and gap analysis. Pediatr Infect Dis J. 2020; 39:949–54.

77. Jacquemard F, Yamamoto M, Costa JM, Romand S, Jaqz-Aigrain E, Dejean A, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG. 2007; 114:1113–21.

78. Plotogea M, Isam AJ, Frincu F, Zgura A, Bacinschi X, Sandru F, et al. Overview of cytomegalovirus infection in pregnancy. Diagnostics (Basel). 2022; 12:2429.

79. Shahar-Nissan K, Pardo J, Peled O, Krause I, Bilavsky E, Wiznitzer A, et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. Lancet. 2020; 396:779–85.

80. Faure-Bardon V, Fourgeaud J, Stirnemann J, Leruez-Ville M, Ville Y. Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy. Ultrasound Obstet Gynecol. 2021; 58:576–81.

81. Egloff C, Sibiude J, Vauloup-Fellous C, Benachi A, Bouthry E, Biquard F, et al. New data on efficacy of valacyclovir in secondary prevention of maternal-fetal transmission of cytomegalovirus. Ultrasound Obstet Gynecol. 2023; 61:59–66.

82. De la Calle M, Baquero-Artigao F, Rodríguez-Molino P, Cabanes M, Cabrera M, Antolin E, et al. Combined treatment with immunoglobulin and valaciclovir in pregnant women with cytomegalovirus infection and high risk of symptomatic fetal disease. J Matern Fetal Neonatal Med. 2022; 35:3196–200.

83. Zammarchi L, Lazzarotto T, Andreoni M, Campolmi I, Pasquini L, Di Tommaso M, et al. Management of cytomegalovirus infection in pregnancy: is it time for valacyclovir? Clin Microbiol Infect. 2020; 26:1151–4.

84. Codaccioni C, Vauloup-Fellous C, Letamendia E, Saada J, Benachi A, Vivanti AJ. Case report on early treatment with valaciclovir after maternal primary cytomegalovirus infection. J Gynecol Obstet Hum Reprod. 2019; 48:287–9.

85. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005; 353:1350–62.

86. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014; 370:1316–26.

87. Kagan KO, Enders M, Schampera MS, Baeumel E, Hoopmann M, Geipel A, et al. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet Gynecol. 2019; 53:383–9.

88. Hughes BL, Clifton RG, Rouse DJ, Saade GR, Dinsmoor MJ, Reddy UM, et al. A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection. N Engl J Med. 2021; 385:436–44.

89. Kagan KO, Enders M, Hoopmann M, Geipel A, Simonini C, Berg C, et al. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. Ultrasound Obstet Gynecol. 2021; 57:560–7.

90. Hamilton ST, Marschall M, Rawlinson WD. Investigational antiviral therapy models for the prevention and treatment of congenital cytomegalovirus infection during pregnancy. Antimicrob Agents Chemother. 2020; 65:e01627–20.

91. Rouse DJ, Fette LM, Hughes BL, Saade GR, Dinsmoor MJ, Reddy UM, et al. Noninvasive prediction of congenital cytomegalovirus infection after maternal primary infection. Obstet Gynecol. 2022; 139:400–6.

92. Practice bulletin no. 151: cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol. 2015; 125:1510–25.

93. Congenital cytomegalovirus infection: update on treatment: scientific impact paper no. 56. BJOG. 2018; 125:e1–11.